Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. ESMO 2017 Congress; abstract LBA2_PR.
Effect van HPV-vaccinatie in Engeland over sociaaleconomische groepen
sep 2024 | Gynaecologische oncologie, Vaccinatie, Virale infecties